{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T05:41:15Z","timestamp":1791438075637,"version":"4.3.3"},"reference-count":75,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T00:00:00Z","timestamp":1753488000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"National Institutes of Health\/National Cancer Institute","award":["P01 CA225517"],"award-info":[{"award-number":["P01 CA225517"]}]},{"name":"National Institutes of Health\/National Cancer Institute","award":["P30 CA015704"],"award-info":[{"award-number":["P30 CA015704"]}]},{"DOI":"10.13039\/100013041","name":"Bloomberg\u223cKimmel Institute for Cancer Immunotherapy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013041","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Marilyn and Michael Glosserman Fund for Basal Cell Carcinoma and Melanoma Research"},{"DOI":"10.13039\/100019050","name":"Barney Family Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020255","name":"Laverna Hahn Charitable Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020255","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Merkel cell carcinoma (MCC) is an aggressive skin cancer with an increased risk of occurrence in immunocompromised patients, including solid organ transplant recipients (SOTRs). As the number of SOTRs rises worldwide, MCC cases in this population are also expected to increase. While anti-programmed cell death 1 ligand 1 (anti-PD-L1; also known as anti-programmed death ligand 1) immunotherapy generates durable tumour responses in \u223c50% of immunocompetent (IC) patients with advanced MCC, its efficacy and safety in SOTRs remain uncertain as these patients have been excluded from most clinical trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To compare baseline characteristics and outcomes among SOTRs and IC patients with MCC, and to evaluate the efficacy and toxicity of anti-PD-L1 in SOTRs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We queried an MCC registry from our institution (April 1988\u2013May 2024), extracting data on demographics, anti-PD-L1 response and immunosuppression regimens, along with incidence of allograft rejection and failure, for analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We identified 1214 patients with MCC (37 SOTRs and 1177 IC patients); 8 of 37 SOTRs received anti-PD-L1. Median time from SOT to MCC diagnosis was 10\u2005years (range 0.4\u201343). The proportion of patients with advanced MCC (\u2265 stage III) was 76% in SOTRs compared with 51% in IC patients (P = 0.004). SOTR status was associated with worse outcomes, including higher rates of disease progression [adjusted hazard ratio (aHR) 2.3], MCC-specific mortality (aHR 3.0) and overall mortality (aHR 3.9) (all P &amp;lt; 0.001 for the respective comparisons). Median time to death due to MCC for SOTRs was 2.7\u2005years; 24% of SOTRs died within one year of diagnosis, in contrast with just 4% of IC patients. Median time to MCC progression for SOTRs was 8.6\u2005months vs. 12\u2005years for IC patients. Among SOTRs, 70% developed distant metastases within 2\u2005years vs. 25% of IC patients. All eight MCC SOTRs treated with anti-PD-L1 were kidney transplant recipients, with five (63%) experiencing an objective response (two complete response, three partial response). However, two patients (29%) experienced irreversible graft failure within 9 weeks.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>SOTR status is a significant independent risk factor of a worse prognosis for MCC. This study represents the largest cohort evaluating the efficacy and safety of anti-PD-L1 in SOTRs with advanced MCC, highlighting the potential benefits in this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/bjd\/ljaf304","type":"journal-article","created":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T11:47:56Z","timestamp":1753444076000},"page":"1221-1231","source":"Crossref","is-referenced-by-count":5,"title":["Merkel cell carcinoma in solid organ transplant recipients: prognosis and response to immunotherapy"],"prefix":"10.1093","volume":"193","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4525-6408","authenticated-orcid":false,"given":"Tomoko","family":"Akaike","sequence":"first","affiliation":[{"name":"Department of Dermatology, University of Washington , Seattle, WA ,","place":["USA"]},{"name":"Albert Einstein College of Medicine , Bronx, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0802-0279","authenticated-orcid":false,"given":"Peter Y","family":"Ch\u2019en","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Washington , Seattle, WA ,","place":["USA"]},{"name":"Fred Hutchinson Cancer Center , Seattle, WA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2427-4404","authenticated-orcid":false,"given":"Daniel S","family":"Hippe","sequence":"additional","affiliation":[{"name":"Albert Einstein College of Medicine , Bronx, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Macy W","family":"Gilmour","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Washington , Seattle, WA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Gong","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Washington , Seattle, WA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Washington , Seattle, WA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neha","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Washington , Seattle, WA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelsey","family":"Cahill","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Washington , Seattle, WA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay","family":"Gunnell","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Washington , Seattle, WA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasreen","family":"Vohra","sequence":"additional","affiliation":[{"name":"Department of Surgery, East Carolina University , Greenville, NC ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Hall","sequence":"additional","affiliation":[{"name":"Albert Einstein College of Medicine , Bronx, NY ,","place":["USA"]},{"name":"Department of Medicine, University of Washington , Seattle, WA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shailender","family":"Bhatia","sequence":"additional","affiliation":[{"name":"Albert Einstein College of Medicine , Bronx, NY ,","place":["USA"]},{"name":"Department of Medicine, University of Washington , Seattle, WA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan J","family":"Lipson","sequence":"additional","affiliation":[{"name":"Department of Oncology, Johns Hopkins University School of Medicine , Baltimore, MD ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8368-6682","authenticated-orcid":false,"given":"Christopher D","family":"Blosser","sequence":"additional","affiliation":[{"name":"Albert Einstein College of Medicine , Bronx, NY ,","place":["USA"]},{"name":"Department of Medicine, University of Washington , Seattle, WA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2784-963X","authenticated-orcid":false,"given":"Paul","family":"Nghiem","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Washington , Seattle, WA ,","place":["USA"]},{"name":"Albert Einstein College of Medicine , Bronx, NY ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,7,26]]},"reference":[{"key":"2025111813171220500_ljaf304-B1","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jaad.2017.10.028","article-title":"Merkel cell carcinoma: current US incidence and projected increases based on changing demographics","volume":"78","author":"Paulson","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"2025111813171220500_ljaf304-B2","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1001\/jamadermatol.2021.6096","article-title":"Recurrence and mortality risk of Merkel cell carcinoma by cancer stage and time from diagnosis","volume":"158","author":"McEvoy","year":"2022","journal-title":"JAMA Dermatol"},{"key":"2025111813171220500_ljaf304-B3","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1126\/science.1152586","article-title":"Clonal integration of a polyomavirus in human Merkel cell carcinoma","volume":"319","author":"Feng","year":"2008","journal-title":"Science"},{"key":"2025111813171220500_ljaf304-B4","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(02)07668-7","article-title":"Merkel cell carcinoma and HIV infection","volume":"359","author":"Engels","year":"2002","journal-title":"Lancet"},{"key":"2025111813171220500_ljaf304-B5","doi-asserted-by":"crossref","first-page":"dju382","DOI":"10.1093\/jnci\/dju382","article-title":"Risk of Merkel cell carcinoma after solid organ transplantation","volume":"107","author":"Clarke","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"2025111813171220500_ljaf304-B6","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jaad.2007.11.020","article-title":"Clinical characteristics of Merkel cell carcinoma at diagnosis in 195 patients: the AEIOU features","volume":"58","author":"Heath","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"2025111813171220500_ljaf304-B7","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1111\/jdv.18256","article-title":"Clinicopathological features, MCPyV status and outcomes of Merkel cell carcinoma in solid-organ transplant recipients: a retrospective, multicentre cohort study","volume":"36","author":"Ferr\u00e1ndiz-Pulido","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025111813171220500_ljaf304-B8","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.34067\/KID.0002472021","article-title":"Global perspective on kidney transplantation: United States","volume":"2","author":"Wang","year":"2021","journal-title":"Kidney360"},{"key":"2025111813171220500_ljaf304-B9","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/ki.2013.494","article-title":"Death from cancer: a sobering truth for patients with kidney transplants","volume":"85","author":"Wong","year":"2014","journal-title":"Kidney Int"},{"key":"2025111813171220500_ljaf304-B10","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1001\/jamadermatol.2015.1702","article-title":"Outcomes of patients with multiple cutaneous squamous cell carcinomas: a 10-year single-institution cohort study","volume":"151","author":"Levine","year":"2015","journal-title":"JAMA Dermatol"},{"key":"2025111813171220500_ljaf304-B11","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa1603702","article-title":"PD-1 Blockade with pembrolizumab in advanced Merkel-cell carcinoma","volume":"374","author":"Nghiem","year":"2016","journal-title":"N Engl J Med"},{"key":"2025111813171220500_ljaf304-B12","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/S1470-2045(16)30364-3","article-title":"Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial","volume":"17","author":"Kaufman","year":"2016","journal-title":"Lancet Oncol"},{"key":"2025111813171220500_ljaf304-B13","doi-asserted-by":"crossref","first-page":"100290","DOI":"10.1016\/j.esmoop.2021.100290","article-title":"Avelumab in patients with previously treated metastatic Merkel cell carcinoma (JAVELIN Merkel 200): updated overall survival data after &gt;5\u2005years of follow-up","volume":"6","author":"D\u2019Angelo","year":"2021","journal-title":"ESMO Open"},{"key":"2025111813171220500_ljaf304-B14","doi-asserted-by":"crossref","first-page":"e002478","DOI":"10.1136\/jitc-2021-002478","article-title":"Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma","volume":"9","author":"Nghiem","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2025111813171220500_ljaf304-B15","doi-asserted-by":"crossref","first-page":"e180077","DOI":"10.1001\/jamaoncol.2018.0077","article-title":"Efficacy and safety of first-line avelumab treatment in patients with stage IV metastatic Merkel cell carcinoma: a preplanned interim analysis of a clinical trial","volume":"4","author":"D\u2019Angelo","year":"2018","journal-title":"JAMA Oncol"},{"key":"2025111813171220500_ljaf304-B16","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1200\/JCO.18.01896","article-title":"Durable tumor regression and overall survival in patients with advanced Merkel cell carcinoma receiving pembrolizumab as first-line therapy","volume":"37","author":"Nghiem","year":"2019","journal-title":"J Clin Oncol"},{"key":"2025111813171220500_ljaf304-B17","doi-asserted-by":"crossref","first-page":"e000654","DOI":"10.1136\/bmjonc-2024-000654","article-title":"Immunotherapy response in immunosuppressed patients with Merkel cell carcinoma: analysis of 183 patients","volume":"4","author":"Gong","year":"2025","journal-title":"BMJ Oncol"},{"key":"2025111813171220500_ljaf304-B18","first-page":"1024","volume-title":"AJCC Cancer Staging Manual","author":"Amin","year":"2017","edition":"Eighth Edition"},{"key":"2025111813171220500_ljaf304-B19","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2025111813171220500_ljaf304-B20","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1200\/JCO.23.02054","article-title":"Circulating tumor DNA assay detects Merkel cell carcinoma recurrence, disease progression, and minimal residual disease: surveillance and prognostic implications","volume":"42","author":"Akaike","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025111813171220500_ljaf304-B21","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1097\/TP.0000000000005007","article-title":"Elevation of donor-derived cell-free DNA before biopsy-proven rejection in kidney transplant","volume":"108","author":"Bromberg","year":"2024","journal-title":"Transplantation"},{"key":"2025111813171220500_ljaf304-B22","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1038\/s41591-024-03087-3","article-title":"Cell-free DNA for the detection of kidney allograft rejection","volume":"30","author":"Aubert","year":"2024","journal-title":"Nat Med"},{"key":"2025111813171220500_ljaf304-B23","doi-asserted-by":"crossref","first-page":"430","DOI":"10.2215\/CJN.11991019","article-title":"Evaluation and treatment of acute rejection in kidney allografts","volume":"15","author":"Cooper","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"2025111813171220500_ljaf304-B24","doi-asserted-by":"crossref","first-page":"a015461","DOI":"10.1101\/cshperspect.a015461","article-title":"Effector mechanisms of rejection","volume":"3","author":"Moreau","year":"2013","journal-title":"Cold Spring Harb Perspect Med"},{"key":"2025111813171220500_ljaf304-B25","doi-asserted-by":"crossref","first-page":"l4923","DOI":"10.1136\/bmj.l4923","article-title":"Prediction system for risk of allograft loss in patients receiving kidney transplants: international derivation and validation study","volume":"366","author":"Loupy","year":"2019","journal-title":"BMJ"},{"key":"2025111813171220500_ljaf304-B26","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1007\/s00262-020-02644-2","article-title":"Impact of corticosteroids on allograft protection in renal transplant patients receiving anti-PD-1 immunotherapy","volume":"69","author":"Danesh","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"2025111813171220500_ljaf304-B27","doi-asserted-by":"crossref","first-page":"4780","DOI":"10.1002\/cncr.33134","article-title":"Clinical outcomes of solid organ transplant recipients with metastatic cancers who are treated with immune checkpoint inhibitors: a single-center analysis","volume":"126","author":"Owoyemi","year":"2020","journal-title":"Cancer"},{"key":"2025111813171220500_ljaf304-B28","doi-asserted-by":"crossref","first-page":"534","DOI":"10.6002\/ect.2023.0018","article-title":"Successful shrinkage of a giant cutaneous squamous cell carcinoma with immunotherapy in a kidney transplant recipient","volume":"21","author":"Eleftheriadis","year":"2023","journal-title":"Exp Clin Transplant"},{"key":"2025111813171220500_ljaf304-B29","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMc1509268","article-title":"Tumor regression and allograft rejection after administration of anti-PD-1","volume":"374","author":"Lipson","year":"2016","journal-title":"N Engl J Med"},{"key":"2025111813171220500_ljaf304-B30","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/CJI.0000000000000188","article-title":"Safe administration of an anti-PD-1 antibody to kidney-transplant patients: 2 clinical cases and review of the literature","volume":"40","author":"Winkler","year":"2017","journal-title":"J Immunother"},{"key":"2025111813171220500_ljaf304-B31","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/CJI.0000000000000180","article-title":"Immune checkpoint inhibitors in organ transplant patients","volume":"40","author":"Kittai","year":"2017","journal-title":"J Immunother"},{"key":"2025111813171220500_ljaf304-B32","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1097\/TP.0000000000002914","article-title":"Poor outcomes with the use of checkpoint inhibitors in kidney transplant recipients","volume":"104","author":"Venkatachalam","year":"2020","journal-title":"Transplantation"},{"key":"2025111813171220500_ljaf304-B33","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1111\/ced.15018","article-title":"Prompt response of advanced cutaneous squamous cell carcinoma to cemiplimab in a kidney transplant patient receiving treatment with everolimus","volume":"47","author":"Gambichler","year":"2022","journal-title":"Clin Exp Dermatol"},{"key":"2025111813171220500_ljaf304-B34","doi-asserted-by":"crossref","first-page":"1041819","DOI":"10.3389\/fneph.2022.1041819","article-title":"Cemiplimab for advanced cutaneous squamous cell carcinoma in kidney transplant recipients","volume":"2","author":"Van Meerhaeghe","year":"2022","journal-title":"Front Nephrol"},{"key":"2025111813171220500_ljaf304-B35","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1038\/s41467-023-37230-4","article-title":"Clonal dynamics of alloreactive T cells in kidney allograft rejection after anti-PD-1 therapy","volume":"14","author":"Dunlap","year":"2023","journal-title":"Nat Commun"},{"key":"2025111813171220500_ljaf304-B36","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1200\/JOP.19.00567","article-title":"Successful administration of cemiplimab to a patient with advanced cutaneous squamous cell carcinoma after renal transplantation","volume":"16","author":"Ali","year":"2020","journal-title":"JCO Oncol Pract"},{"key":"2025111813171220500_ljaf304-B37","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/s40425-019-0653-6","article-title":"Donor-derived cell-free DNA detects kidney transplant rejection during nivolumab treatment","volume":"7","author":"Hurkmans","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"Suppl. 1","key":"2025111813171220500_ljaf304-B38","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/jdv.17407","article-title":"Treatment of metastatic cutaneous squamous cell carcinoma in a solid organ transplant recipient with programmed death-1 checkpoint inhibitor therapy","volume":"36","author":"O\u2019Connell","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025111813171220500_ljaf304-B39","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/CMR.0000000000000651","article-title":"The successful use of pembrolizumab in a renal transplant recipient with metastatic melanoma","volume":"30","author":"Hanna","year":"2020","journal-title":"Melanoma Res"},{"key":"2025111813171220500_ljaf304-B40","doi-asserted-by":"crossref","first-page":"e000908","DOI":"10.1136\/jitc-2020-000908","article-title":"Combination checkpoint blockade for metastatic cutaneous malignancies in kidney transplant recipients","volume":"8","author":"Trager","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"Suppl. 1","key":"2025111813171220500_ljaf304-B41","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/jdv.17658","article-title":"Advanced cutaneous squamous cell carcinoma of the head in two renal transplanted patients treated with cemiplimab","volume":"36","author":"Orte Cano","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025111813171220500_ljaf304-B42","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/onco.13539","article-title":"A pilot study of checkpoint inhibitors in solid organ transplant recipients with metastatic cutaneous squamous cell carcinoma","volume":"26","author":"Tsung","year":"2021","journal-title":"Oncologist"},{"key":"2025111813171220500_ljaf304-B43","doi-asserted-by":"crossref","first-page":"101932","DOI":"10.1016\/j.trim.2023.101932","article-title":"Durable complete response to early immunotherapy discontinuation in a kidney transplant recipient with advanced cutaneous squamous cell carcinoma: a case report and review of literature","volume":"81","author":"Lu","year":"2023","journal-title":"Transpl Immunol"},{"key":"2025111813171220500_ljaf304-B44","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s12882-018-1003-5","article-title":"PD 1 checkpoint inhibition in solid organ transplants: 2 sides of a coin \u2013 case report","volume":"19","author":"Goldman","year":"2018","journal-title":"BMC Nephrol"},{"key":"2025111813171220500_ljaf304-B45","doi-asserted-by":"crossref","first-page":"e291","DOI":"10.1097\/TP.0000000000001861","article-title":"Severe allograft rejection and autoimmune hemolytic anemia after anti-PD1 therapy in a kidney transplanted patient","volume":"101","author":"Deltombe","year":"2017","journal-title":"Transplantation"},{"key":"2025111813171220500_ljaf304-B46","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1111\/ajt.13711","article-title":"Checkpoint inhibitors in kidney transplant recipients and the potential risk of rejection","volume":"16","author":"Alhamad","year":"2016","journal-title":"Am J Transplant"},{"issue":"Suppl. 1","key":"2025111813171220500_ljaf304-B47","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/jdv.17732","article-title":"Value of cemiplimab in progressive metastatic cutaneous squamous cell carcinoma after kidney transplantation: a case report","volume":"36","author":"Geidel","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025111813171220500_ljaf304-B48","doi-asserted-by":"crossref","first-page":"e238037","DOI":"10.1136\/bcr-2020-238037","article-title":"Acute renal transplant rejection following nivolumab therapy for metastatic melanoma","volume":"14","author":"Tan","year":"2021","journal-title":"BMJ Case Rep"},{"key":"2025111813171220500_ljaf304-B49","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1200\/JOP.2017.027326","article-title":"Complete tumor response to pembrolizumab and allograft preservation in renal allograft recipient on immunosuppressive therapy","volume":"14","author":"Sadaat","year":"2018","journal-title":"J Oncol Pract"},{"key":"2025111813171220500_ljaf304-B50","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.jdcr.2017.06.005","article-title":"Complete pathologic response of metastatic cutaneous squamous cell carcinoma and allograft rejection after treatment with combination immune checkpoint blockade","volume":"3","author":"Miller","year":"2017","journal-title":"JAAD Case Rep"},{"key":"2025111813171220500_ljaf304-B51","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s40425-016-0171-8","article-title":"Antitumor activity of nivolumab on hemodialysis after renal allograft rejection","volume":"4","author":"Ong","year":"2016","journal-title":"J Immunother Cancer"},{"key":"2025111813171220500_ljaf304-B52","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1111\/ajt.15071","article-title":"Ipilimumab for the treatment of advanced melanoma in six kidney transplant patients","volume":"18","author":"Zehou","year":"2018","journal-title":"Am J Transplant"},{"key":"2025111813171220500_ljaf304-B53","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ejca.2016.07.026","article-title":"Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient","volume":"67","author":"Herz","year":"2016","journal-title":"Eur J Cancer"},{"key":"2025111813171220500_ljaf304-B54","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1200\/JCO.23.01498","article-title":"Cemiplimab for kidney transplant recipients with advanced cutaneous squamous cell carcinoma","volume":"42","author":"Hanna","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025111813171220500_ljaf304-B55","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13256-017-1229-z","article-title":"Pembrolizumab for metastatic melanoma in a renal allograft recipient with subsequent graft rejection and treatment response failure: a case report","volume":"11","author":"Kwatra","year":"2017","journal-title":"J Med Case Rep"},{"key":"2025111813171220500_ljaf304-B56","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1093\/annonc\/mdw130","article-title":"Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma","volume":"27","author":"Spain","year":"2016","journal-title":"Ann Oncol"},{"key":"2025111813171220500_ljaf304-B57","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.transproceed.2019.09.014","article-title":"Use of ipilimumab and pembrolizumab in metastatic melanoma in a combined heart and kidney transplant recipient: a case report","volume":"52","author":"Soellradl","year":"2020","journal-title":"Transplant Proc"},{"key":"2025111813171220500_ljaf304-B58","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ejca.2018.09.017","article-title":"Anti-PD-1\/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B\/C infection","volume":"104","author":"Tio","year":"2018","journal-title":"Eur J Cancer"},{"key":"2025111813171220500_ljaf304-B59","doi-asserted-by":"crossref","first-page":"574","DOI":"10.3390\/curroncol28010057","article-title":"Safe administration of cemiplimab to a kidney transplant patient with locally advanced squamous cell carcinoma of the scalp","volume":"28","author":"Paoluzzi","year":"2021","journal-title":"Curr Oncol"},{"key":"2025111813171220500_ljaf304-B60","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ejca.2018.03.019","article-title":"Checkpoint blockade after kidney transplantation","volume":"96","author":"Lesouhaitier","year":"2018","journal-title":"Eur J Cancer"},{"key":"2025111813171220500_ljaf304-B61","doi-asserted-by":"crossref","first-page":"376","DOI":"10.36849\/JDD.8234","article-title":"Metastatic Merkel cell carcinoma after simultaneous pancreas-kidney transplantation: fatal outcomes","volume":"23","author":"Burke","year":"2024","journal-title":"J Drugs Dermatol"},{"key":"2025111813171220500_ljaf304-B62","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s40425-019-0585-1","article-title":"Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature","volume":"7","author":"Abdel-Wahab","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2025111813171220500_ljaf304-B63","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1200\/JCO.23.01497","article-title":"Nivolumab + tacrolimus + prednisone \u00b1 ipilimumab for kidney transplant recipients with advanced cutaneous cancers","volume":"42","author":"Schenk","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025111813171220500_ljaf304-B64","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.1097\/TP.0000000000002502","article-title":"Preserved renal allograft function and successful treatment of metastatic Merkel cell cancer post nivolumab therapy","volume":"103","author":"Singh","year":"2019","journal-title":"Transplantation"},{"key":"2025111813171220500_ljaf304-B65","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/jid.2012.388","article-title":"Systemic immune suppression predicts diminished Merkel cell carcinoma-specific survival independent of stage","volume":"133","author":"Paulson","year":"2013","journal-title":"J Invest Dermatol"},{"key":"2025111813171220500_ljaf304-B66","doi-asserted-by":"crossref","first-page":"406","DOI":"10.6004\/jnccn.2022.7009","article-title":"Immune checkpoint inhibitor use in solid organ transplant recipients: a systematic review","volume":"20","author":"Portuguese","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"2025111813171220500_ljaf304-B67","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1097\/TP.0000000000004459","article-title":"Immune checkpoint inhibitors in solid organ transplant recipients with advanced skin cancers-emerging strategies for clinical management","volume":"107","author":"Ferrandiz-Pulido","year":"2023","journal-title":"Transplantation"},{"key":"2025111813171220500_ljaf304-B68","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.jaad.2021.05.042","article-title":"Merkel cell carcinoma patients with solid organ transplant or hematologic malignancy: demographics, survival, and prognosticators","volume":"86","author":"Maloney","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"2025111813171220500_ljaf304-B69","doi-asserted-by":"crossref","first-page":"3564","DOI":"10.1245\/s10434-016-5266-4","article-title":"Analysis of prognostic factors from 9387 Merkel cell carcinoma cases forms the basis for the new 8th edition AJCC staging system","volume":"23","author":"Harms","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"2025111813171220500_ljaf304-B70","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jdcr.2020.11.017","article-title":"Unknown primary Merkel cell carcinoma in the immunosuppressed patient: case series","volume":"8","author":"Rizzo","year":"2021","journal-title":"JAAD Case Rep"},{"key":"2025111813171220500_ljaf304-B71","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.jaad.2012.07.035","article-title":"Unknown primary Merkel cell carcinoma: 23 new cases and a review","volume":"68","author":"Tarantola","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"2025111813171220500_ljaf304-B72","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.kint.2020.12.015","article-title":"A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant","volume":"100","author":"Murakami","year":"2021","journal-title":"Kidney Int"},{"key":"2025111813171220500_ljaf304-B73","doi-asserted-by":"crossref","first-page":"e656","DOI":"10.1097\/TXD.0000000000001113","article-title":"Utility of serial donor-derived cell-free DNA measurements for detecting allograft rejection in a kidney transplant recipient after PD-1 checkpoint inhibitor administration","volume":"7","author":"Lakhani","year":"2021","journal-title":"Transplant Direct"},{"key":"2025111813171220500_ljaf304-B74","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.annonc.2020.03.285","article-title":"Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy","volume":"31","author":"Haanen","year":"2020","journal-title":"Ann Oncol"},{"key":"2025111813171220500_ljaf304-B75","doi-asserted-by":"crossref","first-page":"eadi2012","DOI":"10.1126\/sciadv.adi2012","article-title":"Tumor cell-intrinsic PD-1 promotes Merkel cell carcinoma growth by activating downstream mTOR-mitochondrial ROS signaling","volume":"10","author":"Martins","year":"2024","journal-title":"Sci Adv"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljaf304\/63855287\/ljaf304.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/193\/6\/1221\/63855287\/ljaf304.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/193\/6\/1221\/63855287\/ljaf304.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T18:17:38Z","timestamp":1763489858000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/193\/6\/1221\/8213982"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,26]]},"references-count":75,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,7,26]]},"published-print":{"date-parts":[[2025,11,18]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljaf304","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,7,26]]}}}